UTAH MEDICAL PRODUCTS INC
For the period ended Nov 4, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2025 · Filed Nov 4, 2025
Contents
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 4, 2025
| UTAH MEDICAL PRODUCTS, INC. | ||
|---|---|---|
| (Exact name of registrant as specified in its charter) | ||
| Utah | 000-12575 | 87-0342734 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer |
| incorporation or organization) | Identification No.) | |
| 7043 South 300 West | ||
| Midvale, Utah | 84047 | |
| (Address of principal executive offices) | (Zip code) | |
| Registrant’s telephone number, including area code: | Phone: (801) 566-1200 | |
| n/a | ||
| (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter). | |
| Emerging growth company ☐ | |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] | |
ITEM 5.02— DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On October 31, 2025, the Board of Directors of Utah Medical Products, Inc. (UTMD) voted to increase the size of the Board of Directors from five to six members and to appoint Kevin Timken to fill the vacancy created by the increase in the number of directors. Mr. Timken will serve on the Board’s Audit Committee and Compensation and Benefits Committee.
Mr. Timken was Partner, Co-Leader of Securities and Capital Markets at Michael Best & Friedrich, LLP from 2017 to 2025, and Partner, Kruse Land Maycock & Ricks, LLC from 2000 to 2017, during which 25-year time span he advised UTMD on U.S. Securities and Exchange Commission matters. Mr. Timken obtained a J.D. degree from the University of Utah College of Law in 1997, and a B.A. cum laude in English from the University of Northern Colorado in 1987.
As a member of the Board of directors, Mr. Timken received a grant of 10,000 stock options with an exercise price of $58.10 per share that will vest over a four-year period if he remains a member of the Board of Directors, and will receive the UTMD standard Board Member fee of $7,650 per quarter, which will be pro-rated for the final quarter of 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.